Trypsinogen and chymotrypsinogen: potent anti-tumor agents

González-Titos, A.; Hernández-Camarero, P.; Barungi, S.; Marchal, J.A.; Kenyon, J.; Perán, M.

Revista: Expert Opinion on Biological Therapy

ISSN: 1744-7682

Año de publicación: 2021

Volumen: 21

Número: 12

Páginas: 1609-1621

DOI: 10.1080/14712598.2021.1922666


Introduction: Trypsinogen and chymotrypsinogen have been used clinically in tissue repair due to their ability to resolve inflammatory symptoms. Recently, novel evidence has supported the anti-tumourigenic potential of a mixture of trypsinogen and chymotrypsinogen.

Areas covered: First, we analyze the structure of these proteases and the effects of pancreatic proteinases on tissue repair, inflammation and the immune system. Second, we summarize studies that provided evidence of the effects of pancreatic (pro)enzymes on tumor cells both in vitro and in vivo and some successful clinical applications of pancreatic (pro)enzymes. Finally, we study pancreatic (pro)enzymes potential molecular targets, such as the proteinase-activated receptors (PARs).

Expert opinion: This novel therapy has been shown to have effective antitumor effects. Treatment with these (pro) enzymes sensitizes Cancer Stem Cells (CSCs) which may allow chemotherapy and radiotherapy to be more effective, which could positively affect the recovery of cancer patients.